Software Platform Integrates Interventional Image-Guided Procedures

A new interventional applications platform combines physiology, imaging, and co-registration tools to provide cardiac and peripheral vascular patients with superior care.

The Royal Philips (Amsterdam, The Netherlands) IntraSight interventional applications platform is a scalable system based on Philips’ common software and hardware architecture. IntraSight provides seamless integration with the Allura and Azurion iXR image-guided therapy (IGT) systems, optimizing interventional lab performance with new tableside touch screen control, data management, and Philips remote services (PRS) diagnostics that provide corrective action planning, improved uptime, increased case efficiency, and reduced errors.


The comprehensive applications suite includes instant wave free ratio (iFR), fractional flow reserve (FFR), intravascular ultrasound (IVUS), and co-registration modalities to simplify complex interventions and speed routine procedures. Patient information is thus entered only once, generating a single case menu that is shared between iFR/FFR and IVUS modalities, which can also be imported from Azurion or Allura coronary suites with a touch of a button. For non-Philips catheterization labs, the data can be imported using digital imaging and communications in medicine (DICOM) worklists.

iFR is an innovative pressure-derived index proprietary to Philips, allowing a simplified hyperemia-free physiological assessment of coronary blockages. Using iFR pullback and co-registration and IVUS co-registration with the angiogram, interventional physicians can identify the precise locations that are causing ischemia, map both the pressure profile and IVUS measurements of the whole vessel onto the angiogram, plan stent length and placement with the aid of a virtual stent, and predict potential physiologic improvement.

“The range and complexity of cardiovascular diseases that can be treated with minimally invasive procedures continues to expand. The procedures themselves are also becoming more complex, increasing the demands on physicians to integrate different sources of information, decide on the best course of treatment for each patient, act on that decision and confirm the treatment’s effectiveness,” said Bert van Meurs, chief business leader of IGT at Royal Philips. “IntraSight is an important step forward in integrating intravascular diagnostic applications into a smart, simple and seamless workflow in the interventional lab.”

“IntraSight has made an immediate impact in our lab,” said Rasha Al-Lamee, MD, clinical academic interventional cardiology consultant at Imperial College Healthcare NHS Trust (London, United Kingdom). “It is so simple and intuitive to use that it took us no time at all to get used to it. It has made using physiology and imaging even quicker and easier, which is a great advance for us and for our patients.”